The Indian pharmaceutical industry is set for significant growth, with a projected CAGR of over 10%, expected to reach US$130 billion by 2030.
Probe42 provides comprehensive data on more than 22,000 pharmaceutical businesses in India.
Indian pharmaceutical incorporations trace back to the 1900s, showing consistent growth till the 1970s, and a significant spike since the 2000s, with over 1000 new incorporations annually since 2015.
Dive into the dynamic world of Indian Pharma with our Industry Insights series, covering geographic distribution, financial insights, and revenue breakdown in key pharmaceutical sectors, including Pharma Retailers and Distributors, Formulations, API Manufacturers, Contract Research, and Animal Pharma.
Key Highlights:
🔸60% of secured loans in the industry stem from Maharashtra, Telangana, Gujarat, and Delhi
🔹 Over 50% of pharmaceutical companies have not initiated any secured loans, with the majority having a total sum of <=₹1 Cr in secured loans.
🔸 Majority of Pharma retailers, distributors, and Formulation companies have secured borrowings <=₹1 Cr, while API Manufacturing companies typically range between ₹25 Cr- 100 Cr.
🔹 Annual revenue of pharmaceutical companies spans from as low as ₹1,000 to as high as ₹20,000 Cr.
🔸 Foreign currency earnings in the industry can reach up to ₹8,000 Cr, whereas foreign currency expenses total around ₹800 Cr.
—————————————————————————————————————————————————
About Probe42
- Probe42 is an independent information services company that specializes in offering financial information on unlisted Indian companies.
- Our platform has been widely utilized by banks and corporations to aid key processes like business development, credit analysis, KYC and competitor analysis.
- Access over 1.9 Million Active companies, with 500+ Data points on each company, curated from 746 verified data sources on a single platform.
